Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2014

View Archived Issues

Researchers design genome editing system to correct hereditary gene dysfunction

Chloroquine derivative developed for improving anticancer activity

Jubilant Biosys identifies compounds active against mutant EGFR

CCTA-1523 reverses ABCG2-mediated multidrug resistance in cancer cells

Scientists at Roche disclose novel benzimidazoles as CNS active agents

AbbVie presents highlights of first quarter 2014

Novel agent for neuropsychiatric disorders presented by IntraCellular Therapies

Novavax discloses data from phase II study of RSV vaccine

Sanofi patents novel protein kinase inhibitors for cancer

Researchers at Novartis present new capsular saccharides for immune responses

French researchers disclose new agents for HIV infection

Scientists at Orion Corp. design new TRPA1 antagonists

IMM-H007 reduces atherosclerotic plaque in mice and increases circulating HDL levels

Oxford BioMedica provides update on RetinoStat program

Preclinical results presented for InvaplexAR, a Shigella vaccine

GSK and MMV begin phase III program of tafenoquine

Amicus Therapeutics reports data from phase III trial of migalastat

Crinetics Pharmaceuticals receives grant to develop sst agonists for ophthalmic use

Glenmark's anti-TrkA antibody for chronic pain to enter phase I

AstraZeneca declines latest offer from Pfizer

Ambrx and Zhejiang Hisun form cancer collaboration

First approval of Otsuka's Deltyba for tuberculosis

Biota receives stop-work order on activities related to contract with BARDA

ReGenX and AAVLife sign license agreement in Friedreich's ataxia

Meda rejects Mylan merger proposal

Bristol-Myers Squibb acquires iPierian

FDA approves Zykadia for ALK+ non-small cell lung cancer